SymbolQNCX
NameQUINCE THERAPEUTICS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
Address611 GATEWAY BLVD,SUITE 273, SOUTH SAN FRANCISCO, California, 94080, United States
Telephone+1 415 910-5717
Fax
Email
Websitehttps://www.quincetx.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001662774
Description

Quince Therapeutics, Inc., is a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases. The companys Phase 3 lead asset, EryDex, is the first product in development that leverages its proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patients own red blood cells.

Additional info from NASDAQ:
Quince Therapeutics, Inc., is a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases. The companys Phase 3 lead asset, EryDex, is the first product in development that leverages its proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patients own red blood cells.

2026-06-30 12:00

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

Read more
2026-06-26 17:31

New Form 8-K/A - Quince Therapeutics, Inc. <b>Filed:</b> 2026-06-26 <b>AccNo:</b> 0001193125-26-285572 <b>Size:</b> 147 KB <br />Item 3.03: Material Modifications to Rights of Security Holders

Read more
2026-06-26 13:18

(99% Neutral) QUINCE THERAPEUTICS, INC. (QNCX) Announces Executive Changes

Read more
2026-06-15 21:57

Lamond David 🟢 acquired 2.7K shares (1 derivative) of Quince Therapeutics, Inc. (QNCX) at $0.95 Transaction Date: Jun 11, 2026 | Filing ID: 000832

Read more
2026-06-15 21:51

Senner Christopher J. 🟢 acquired 2.7K shares (1 derivative) of Quince Therapeutics, Inc. (QNCX) at $0.95 Transaction Date: Jun 11, 2026 | Filing ID: 000830

Read more
2026-06-11 21:30

Roberts Brigette 🟢 acquired 16.7M shares (9 derivative) of Quince Therapeutics, Inc. (QNCX) at $0.84 ($11.8M) Transaction Date: May 18, 2026 | Filing ID: 000004

Read more
2026-06-11 21:06

(99% Neutral) QUINCE THERAPEUTICS, INC. (QNCX) Announces Regulatory Update

Read more
2026-06-11 18:28

New Form 3 - Quince Therapeutics, Inc. <b>Filed:</b> 2026-06-11 <b>AccNo:</b> 0001346566-26-000003 <b>Size:</b> 11 KB

Read more
2026-06-11 13:02

New Form D - Quince Therapeutics, Inc. <b>Filed:</b> 2026-06-11 <b>AccNo:</b> 0000912282-26-000811 <b>Size:</b> 11 KB

Read more
2026-06-11 13:01

New Form D - Quince Therapeutics, Inc. <b>Filed:</b> 2026-06-11 <b>AccNo:</b> 0000912282-26-000809 <b>Size:</b> 11 KB

Read more